Clinical Trial Update: Safety Study of Low Dose Interleukin 2 (IL-2) Plus PEG-IFN/RBV In Chronic Hepatitis C Virus Genotype I [Phase 1]

View source ↗

Summary

A Phase 1 safety study of low-dose interleukin-2 combined with PEG-IFN/RBV for chronic hepatitis C genotype I was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Interleukin-2 (interleukin-2)
• Pegylated Interferon Alfa-2b (pegylated interferon alfa-2b)
• Ribavirin (ribavirin)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Hepatitis C | Phase 1 | Status: TERMINATED